Skip to main content
    Q

    Q32 Bio Inc (QTTB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.29
    -0.42 (-4.82%)

    Market Cap: $260.64M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Q32 Bio Inc (QTTB) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Q32 Bio reported revenue of $53.74M for the fiscal year ended Dec 31, 2025. That year, net income was $29.82M with a net margin of 55.5%, operating cash flow was -$33.54M and free cash flow was -$33.54M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$8.92M.

    Revenue and Margins

    The operating margin was 31.5% in the fiscal year ended Dec 2025. Over the 7 years to Dec 2025, revenue grew from $5.32M, a compound annual rate of 39.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$53.74MN/A100.0%31.5%55.5%
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023-$6.65M-307.3%N/AN/AN/A
    Dec 2022$3.21M-90.6%100.0%-4154.6%-156.0%
    Dec 2021$33.97M+1157.3%100.0%-282.4%-281.9%
    Dec 2020$2.70M+62.2%100.0%-4821.0%-4762.9%
    Dec 2019$1.67M-68.7%100.0%-6599.2%-6237.5%
    Dec 2018$5.32MN/A100.0%-1126.0%-1044.3%
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$53.74M$0-$6.65M$3.21M$33.97M$2.70M$1.67M$5.32M$0N/A
    Cost of revenue$0$0$0$0$0$0$0$0$0$239.80K
    Gross profit$53.74M$0-$6.65M$3.21M$33.97M$2.70M$1.67M$5.32M$0-$239.80K
    Research and development$19.16M$48.14M$31.73M$98.35M$93.08M$100.39M$89.40M$47.95M$21.38M$5.69M
    Operating income$16.90M-$66.10M-$48.26M-$133.28M-$95.95M-$130.26M-$109.94M-$59.93M-$29.66M-$10.00M
    Net income$29.82M-$47.73M-$53.74M-$5.00M-$95.76M-$128.69M-$103.92M-$55.58M-$29.99M-$8.05M
    EBITDA$30.39M-$45.63MN/A-$2.69M-$88.49M-$122.50M-$103.63MN/AN/A-$7.81M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$53.74M$0$0$0$0$0$0$0-$14.66M
    Gross profit$0$0$0$53.74M$0$0$0-$120.00K$0$0$0-$14.66M
    Operating income-$10.66M-$9.12M-$7.72M$45.88M-$7.58M-$9.17M-$12.23M-$14.53M-$18.81M-$17.92M-$14.84M-$25.81M
    Net income-$8.92M-$8.95M-$7.61M$57.73M-$7.39M-$9.49M-$11.03M-$14.19M-$17.59M-$16.98M$1.03M-$27.07M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $9.71M by $38.59M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$61.78M$92.33M$47.06M$228.47M$211.72M$263.74M$310.57M$259.09M$137.53M$14.22M
    Current assets$55.05M$81.88M$28.72M$181.01M$191.91M$219.56M$266.58M$221.69M$131.60M$11.99M
    Cash and equivalents$48.30M$77.97M$25.62M$33.99M$108.38M$217.43M$53.77M$38.22M$51.58M$11.39M
    Total liabilities$19.76M$86.66M$118.53M$50.49M$42.07M$67.74M$52.06M$62.74M$39.22M$6.72M
    Short-term debt$6.24M$3.10M$878.00K$32.87M$246.00K$2.50MN/AN/AN/AN/A
    Long-term debt$3.47M$9.56M$43.18M$5.07M$4.97MN/AN/AN/AN/AN/A
    Shareholder equity$42.01M$5.67M-$182.92M$177.98M$169.65M$196.00M$258.51M$196.35M-$39.45M$7.50M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$297.20M$115.87M$63.67M$61.78M$57.78M$66.12M$79.07M$92.33M$104.54M$124.21M$152.33M$47.06M
    Total liabilities$9.53M$9.96M$17.36M$19.76M$76.23M$78.35M$83.08M$86.66M$86.25M$90.70M$103.56M$229.98M
    Cash and equivalents$289.59M$106.27M$50.75M$48.30M$49.04M$54.83M$65.48M$77.97M$89.08M$97.66M$115.51M$25.62M
    Shareholder equity$287.67M$105.91M$46.31M$42.01M-$18.45M-$12.23M-$4.01M$5.67M$18.30M$33.51M$48.77M-$182.92M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$33.54M-$67.72M-$18.68M-$113.66M-$109.75M-$94.33M-$91.36M-$42.56M$6.48M-$8.48M
    Capital expenditures$0$75.00K$5.00K$1.28M$2.40M$3.73M$21.83M$24.94M$1.96M$1.99M
    Free cash flow-$33.54M-$67.79M-$18.68M-$114.95M-$112.15M-$98.06M-$113.19M-$67.50M$4.52M-$10.47M
    Investing cash flow$7.00M$19.93M-$5.00K$36.72M-$50.79M$204.90M-$51.80M-$121.79M-$81.53M-$2.27M
    Financing cash flow-$3.13M$95.14M$406.00K$596.00K$52.17M$53.09M$158.21M$150.99M$115.23M$378.31K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$4.42M-$3.08M-$6.34M-$6.18M-$4.23M-$10.65M-$12.48M-$11.43M-$19.52M-$22.21M-$14.55M-$10.71M
    Capital expendituresN/AN/A$0$0$0$2.00K$0$2.00K$58.00K$15.00K$0$0
    Free cash flowN/AN/A-$6.34M-$6.18M-$4.23M-$10.65M-$12.48M-$11.43M-$19.58M-$22.23M-$14.55M-$10.71M
    Last 12 quarters

    Frequently Asked Questions About QTTB

    What is Q32 Bio's annual revenue?

    Q32 Bio reported revenue of $53.74M for the fiscal year ended Dec 31, 2025.

    Is Q32 Bio profitable?

    Yes. Q32 Bio reported net income of $29.82M for the fiscal year ended Dec 31, 2025, with a net margin of 55.5%.

    How much free cash flow does QTTB generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$33.54M minus capital expenditures of $0 produced free cash flow of -$33.54M.

    How much debt does Q32 Bio have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $3.47M, short-term debt of $6.24M and cash and equivalents of $48.30M.

    What is QTTB's profit margin?

    For the fiscal year ended Dec 31, 2025, Q32 Bio reported gross margin of 100.0%, operating margin of 31.5% and net margin of 55.5%.